Tibulizumab  (Synonyms: LY 3090106)

Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research^[1].

Tibulizumab (LY 3090106) binds to mouse BAFF with a K_D of 340 nM and does not bind to mouse IL-17. Tibulizumab binds to cynomolgus BAFF and cynomolgus IL-17 with K_D of 26.8 pM and 19 pM, respectively^[1].
In HT-29 cells, Tibulizumab antagonizes the IL-17-induced secretion of CXCL1 in a concentration-dependent manner (IC₅₀ of 2.00 nM). In T1165 cells, Tibulizumab blocks BAFF-induced proliferation in a concentration-dependent manner (IC₅₀ of 0.064 nM). Tibulizumab simultaneously binds and blocks both BAFF and IL-17^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tibulizumab (LY 3090106; 660 µg/mouse, i.p; 66 µg/mouse, s.c) effectively antagonizes the biological effects induced by human BAFF and IL-17 in the mouse^[1].
In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1849636-24-3

[Tibulizumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Robert J Benschop, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019 Aug/Sep;11(6):1175-1190.  [Content Brief]